Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:47:35 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:TFFP from 2023-05-04 to 2024-05-03 - 36 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 17:07U:TFFPNews ReleaseTFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
2024-04-29 20:00U:TFFPNews ReleaseTFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
2024-04-29 10:00U:TFFPNews ReleaseTFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
2024-04-15 07:00U:TFFPNews ReleaseTFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
2024-03-28 16:05U:TFFPNews ReleaseTFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-27 16:01U:TFFPNews ReleaseTFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
2024-03-25 09:01U:TFFPNews ReleaseTFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (I
2024-03-22 15:12U:TFFPNews ReleaseTFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2024-03-20 12:00U:TFFPNews ReleaseTFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
2024-03-20 09:04U:TFFPNews ReleaseTFF Pharmaceuticals Announces Update on Clinical Programs
2024-03-14 16:48U:TFFPNews ReleaseTFF Pharmaceuticals to Participate in the 36th Annual Roth Conference - March 17-19, 2024
2024-01-24 08:00U:TFFPNews ReleaseTFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference ‚  
2024-01-09 08:00U:TFFPNews ReleaseTFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
2023-12-19 06:00U:TFFPNews ReleaseTFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
2023-12-18 16:01U:TFFPNews ReleaseTFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC
2023-12-15 07:00U:TFFPNews ReleaseTFF Pharmaceuticals Announces Reverse Stock Split
2023-12-13 08:00U:TFFPNews ReleaseTFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
2023-11-30 08:00U:TFFPNews ReleaseTFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
2023-11-30 08:00U:TFFPNews ReleaseTFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors
2023-11-27 07:00U:TFFPNews ReleaseTFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference ¢ € “ December 7, 2023
2023-11-14 16:05U:TFFPNews ReleaseTFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-08 16:05U:TFFPNews ReleaseTFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing
2023-11-07 16:05U:TFFPNews ReleaseTFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023
2023-10-02 17:00U:TFFPNews ReleaseTFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines
2023-09-28 16:30U:TFFPNews ReleaseTFF Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-08-23 07:00U:TFFPNews ReleaseTFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference ¢ € “ September 11-13, 2023
2023-08-17 16:01U:TFFPNews ReleaseTFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
2023-08-15 06:05U:TFFPNews ReleaseTFF Pharmaceuticals Reports ‚  Second Quarter 2023 Financial Results and Provides Corporate Update
2023-08-15 06:00U:TFFPNews ReleaseTFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock
2023-08-14 16:02U:TFFPNews ReleaseTFF Pharmaceuticals Announces Proposed Public Offering of Common Stock
2023-08-09 08:30U:TFFPNews ReleaseTFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023
2023-07-31 07:00U:TFFPNews ReleaseTFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infec
2023-06-26 07:00U:TFFPNews ReleaseTFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine
2023-05-23 16:05U:TFFPNews ReleaseTFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
2023-05-11 16:05U:TFFPNews ReleaseTFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
2023-05-04 08:00U:TFFPNews ReleaseTFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases